Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America
Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results
SABCS 2024: Highlights in breast cancer genomic testing
Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC